Andexanet alfa - specific antidote to severe bleeding after a treatment with apixaban or rivaroxaban

Abstract

A review of a new antidote for direct oral inhibitors of FXa, apixaban and rivaroxaban, andexanet alfa (Ondexxya(R)), has been reviewed. The results of ongoing phase I-III/VI clinical trials are presented with its dosage for the life-threatening bleeding.

Keywords

• antidote
• Fxa inhibitor
• andexanet alfa
• bleeding